Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc R Theoret

Showing results (11-20 of 111) with videos related to

Pageof 12
Sort By:
Cancer Research|July 16, 2010
Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancerRajeev K Shrimali, Zhiya Yu, Marc R Theoret, et al.
Clinical Genitourinary Cancer|July 25, 2007
Phase I trial of an enhanced prostate-specific antigen-based vaccine and anti-CTLA-4 antibody in patients with metastatic androgen-independent prostate cancerMarc R Theoret, Philip M Arlen, Mary Pazdur, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 4, 2025
FDA Approval Summary: Idecabtagene Vicleucel for the Treatment of Triple-Class-Exposed, Relapsed or Refractory Multiple MyelomaPoornima Sharma, Xue Lin, Zhenzhen Xu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 20, 2022
FDA Approval Summary: Idecabtagene Vicleucel for Relapsed or Refractory Multiple MyelomaPoornima Sharma, Bindu Kanapuru, Bindu George, et al.
Nature Immunology|June 13, 2025
The BCR-SEQC initiativeRittika Mallik, Rebecca Kusko, Andrea C Baines, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 9, 2010
Development of human anti-murine T-cell receptor antibodies in both responding and nonresponding patients enrolled in TCR gene therapy trialsJeremy L Davis, Marc R Theoret, Zhili Zheng, et al.
Dermatology Online Journal|June 7, 2022
Impact of an evolving regulatory landscape on skin cancer drug development in the U.SDavid M Miller, Sophia Z Shalhout, Denise Casey, et al.
Cancer Discovery|July 22, 2021
Rethinking Cancer Clinical Trial Conduct Induced by COVID-19: An Academic Center, Industry, Government, and Regulatory Agency PerspectiveKeith T Flaherty, James H Doroshow, Susan Galbraith, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 15, 2025
FDA Approval Summary: Lisocabtagene Maraleucel for Relapsed or Refractory Follicular LymphomaKristen Britton, Upendra Mahat, Nicholas C Richardson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 1, 2017
FDA Approval Summary: Eribulin for Patients with Unresectable or Metastatic Liposarcoma Who Have Received a Prior Anthracycline-Containing RegimenChristy L Osgood, Meredith K Chuk, Marc R Theoret, et al.
Pageof 12

Showing results (11-20 of 111) with videos related to

Sort By:
Pageof 12
Cancer Research|July 16, 2010
Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancerRajeev K Shrimali, Zhiya Yu, Marc R Theoret, et al.
Clinical Genitourinary Cancer|July 25, 2007
Phase I trial of an enhanced prostate-specific antigen-based vaccine and anti-CTLA-4 antibody in patients with metastatic androgen-independent prostate cancerMarc R Theoret, Philip M Arlen, Mary Pazdur, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 4, 2025
FDA Approval Summary: Idecabtagene Vicleucel for the Treatment of Triple-Class-Exposed, Relapsed or Refractory Multiple MyelomaPoornima Sharma, Xue Lin, Zhenzhen Xu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 20, 2022
FDA Approval Summary: Idecabtagene Vicleucel for Relapsed or Refractory Multiple MyelomaPoornima Sharma, Bindu Kanapuru, Bindu George, et al.
Nature Immunology|June 13, 2025
The BCR-SEQC initiativeRittika Mallik, Rebecca Kusko, Andrea C Baines, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 9, 2010
Development of human anti-murine T-cell receptor antibodies in both responding and nonresponding patients enrolled in TCR gene therapy trialsJeremy L Davis, Marc R Theoret, Zhili Zheng, et al.
Dermatology Online Journal|June 7, 2022
Impact of an evolving regulatory landscape on skin cancer drug development in the U.SDavid M Miller, Sophia Z Shalhout, Denise Casey, et al.
Cancer Discovery|July 22, 2021
Rethinking Cancer Clinical Trial Conduct Induced by COVID-19: An Academic Center, Industry, Government, and Regulatory Agency PerspectiveKeith T Flaherty, James H Doroshow, Susan Galbraith, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 15, 2025
FDA Approval Summary: Lisocabtagene Maraleucel for Relapsed or Refractory Follicular LymphomaKristen Britton, Upendra Mahat, Nicholas C Richardson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 1, 2017
FDA Approval Summary: Eribulin for Patients with Unresectable or Metastatic Liposarcoma Who Have Received a Prior Anthracycline-Containing RegimenChristy L Osgood, Meredith K Chuk, Marc R Theoret, et al.
Pageof 12